Sign in

Serum Institute’s Covishield supplies begin moving from Pune unit for distribution across nation

The Government of India formally sent a purchase order to the company on Monday evening for 11 million doses of Covishield, at a special price of Rs200 per dose for the first million doses

Published on: Jan 12, 2021, 08:20:42 IST
Share
Share via
  • facebook
  • twitter
  • linkedin
  • whatsapp
Copy link
  • copy link

Supplies of Covishield, Serum Institute of India’s Oxford-AstraZeneca vaccine against Coronavirus disease (Covid-19), have begun moving from the company’s manufacturing facility in Pune early today.

Police personnel guard the trucks to be used to transport the Covishield vaccine from Serum Institute of India to different parts of the country, in Pune on January 11. (PTI)
Police personnel guard the trucks to be used to transport the Covishield vaccine from Serum Institute of India to different parts of the country, in Pune on January 11. (PTI)

The supplies will further be distributed to close to 60 cold storage points spread across the country for the nationwide vaccination drive on January 16 .

The first step after a purchase is made is for the manufacturer to deliver supplies by air to the primary vaccine stores run by the Union health ministry, which are called Government Medical Stores Depot (GMSD).

There are four such large depots functional at the moment in the country , one each in Karnal, Mumbai, Chennai and Kolkata. A manufacturer will deliver to one of these depots or sometimes even multiple depots, depending on the agreement signed with the government.

From these main depots, the supplies will be diverted to two points in refrigerated or insulated vans. One of the deployment points is the state vaccine stores that are 56 in number spread across various states.

From there on, it is the responsibility either of the state governments or Union Territory administration to deploy the stock further as per the state requirement. From the state stores, the supplies will be sent in refrigerated and insulated vans to the district vaccine stores, which is also a temperature control facility,

The Government of India formally sent a purchase order to the company on Monday evening for 11 million doses of Covishield, at a special price of Rs200 per dose for the first million doses.

SII is the local manufacturers for Oxford-AstraZeneca vaccine, and has also conducted clinical trials of the vaccine in India. Currently, phase 3 trials are going on in the country.

Initially, the deal is for procuring 11 million doses that is expected to cover the first phase of the vaccination drive involving 10 million healthcare workers across the country. There is also the plan to procure about 45 million more doses by April, 2021.

The government is keeping a margin of about 10%, to factor in wastage possibility of the vaccine, especially at the vaccination sites.

  • Rhythma Kaul
    ABOUT THE AUTHOR
    Rhythma Kaul

    Rhythma Kaul is the national health editor of the Hindustan Times. She has been reporting on public health, medicine, and medical research, with a particular focus on how government decisions and health system reforms shape people’s lives. Rhythma has over 25 years of journalistic experience. She joined Hindustan Times in 2008, and has since covered everything from pandemics and infectious diseases to cutting‑edge medical research and climate‑related health challenges. Her stories routinely track the work of the Ministry of Health and Family Welfare, department of pharmaceuticals, and key national health programmes, making complex medical science and policy accessible to a wide audience. One of her prominent news breaks has been the 2012 Baby Falak case: A two-year-old brutally battered baby girl was admitted to AIIMS-Delhi with severe head injuries, multiple fractures, human bite marks, and burns. The police investigation revealed this to be a case of multi-state human-trafficking racket. She was profiled by The Wall Street Journal for breaking this story. Rhythma holds a Master’s degree from Jawaharlal Nehru University, Delhi. Prior to Hindustan Times, she worked with the India Today Group. Rhythma can be contacted at rhythma.kaul@hindustantimes.com. Her X handle is @RamblingBrook.Read More